Progressive multiple sclerosis: Desperately seeking remedy

The Lancet Neurology

Volumn 12, Issue 9, 2013, Pages 840-841

  Stuve, Olaf ^a,b,c,d   Paul, Friedemann ^a,b,c,d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DRONABINOL; PLACEBO;

BRAIN ATROPHY; BRAIN DISEASE; CLINICAL TRIAL; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; HUMAN; LETTER; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PRIORITY JOURNAL; SPASTICITY;

CANNABINOID RECEPTOR AGONISTS; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; TETRAHYDROCANNABINOL;

EID: 84881553088     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(13)70181-9     Document Type: Letter

References (10)

1. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989, 112:133-146.
2. Tremlett H, Zhao Y, Rieckmann P, Hutchinson M New perspectives in the natural history of multiple sclerosis. Neurology 2010, 74:2004-2015.
3. Lublin FD, Reingold SC Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996, 46:907-911.
4. Kieseier BC, Stuve O A critical appraisal of treatment decisions in multiple sclerosis-old versus new. Nat Rev Neurol 2011, 7:255-262.
5. Goodman AD, Brown TR, Edwards KR, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010, 68:494-502.
6. Zajicek J, Ball S, Wright D, et al. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurol 2013, on behalf of the CUPID investigator group, published online July 13. http://dx.doi.org/10.1016/S1474-4422(13)70159-5.
7. Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
8. Gowran A, Noonan J, Campbell VA The multiplicity of action of cannabinoids: implications for treating neurodegeneration. CNS Neurosci Ther 2011, 17:637-644.
9. Hasseldam H, Johansen FF Cannabinoid treatment renders neurons less vulnerable than oligodendrocytes in experimental autoimmune encephalomyelitis. Int J Neurosci 2011, 121:510-520.
10. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003, 362:1517-1526. on behalf of the UK MS Research Group.